Nice post Leonard. I completely agree with you. As the only game in town for Fragile X, if we have good clinical trial results this stock explodes higher in my opinion. Much, much higher. I think we all agree the reaction to the SAE's is insanely overblown, but there's the perception that kids with DEE have other options (was one, now two). Not so with Fragile X. An infection at the spot where the patch is placed wouldn't deter ANYONE from using the patch if it could prevent FX. I've said many times on this board that I bought ZYNE primarily because of my belief in getting approval for FX, and that anything else would just be extra. Obviously ASD would be incredible as well, but FX has always been the one for me. I've bought this stock 4 times since the DEE results came out. I'm running out of money, but building a war chest of shares lol. I'm extremely confident that any shares bought under $15 will be a fantastic purchase, and buys at these levels will make patient investors very wealthy.
News 
Market Data 
Discover 
AI
